• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hematological Cancers Drug Pipeline Update 2006 Lists More Than 230 Drugs and Gives You a Progress Analysis on Each One of Them

Posted on: Tuesday, 21 November 2006, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c45602) has announced the addition of Hematological Cancers Drug Pipeline Update 2006 to their offering.

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

There are today more than 230 emerging therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs.

Hematological Cancers Drug Pipeline Update 2006 lists more than 230 drugs and gives you a progress analysis on each one of them. Read more below how this Drug Pipeline Update is organized:

Investigators Includes more than 160 investigators

Drug name & Synonyms Lists commercial, generic and code names for drugs. In several hundreds of synonym names.

Developmental stage

Contains more than 230 drugs in active development:

- 50 marketed drugs

- 25 projects in Phase III

- 100 projects in Phase II

- 50 projects in Phase I

- 40 projects in Preclinical

Line of treatments Major lines of treatment, including

- Antibodies

- Cytokines

- Small molecules

- Vaccines

Mechanisms Includes more than 140 mechanisms of action:

- Apoptosis agonists

- CD molecules antagonists

- DNA antagonists

- DNA topoisomerase ATP hydrolysing inhibitors

- Microtubule inhibitors

- Immunostimulants

- Protein kinase inhibitors

- Ribonucleoside diphosphate reductase inhibitors

Etc.

Compounds Lists compound name or type of compound:

- Antibodies

- Chemical names

- Enzymes

- Nucleotides

- Peptides

- Proteins

- Ribozymes

Etc.

Description Progress analysis and review of drug development.

A typical drug profile reports on:

- Drug Name & Synonyms

- Investigator(s)

- Indication(s)

- Developmental Stage(s)

- Mechanism(s)

- Target(s)

- Clinical Development

- Developmental History

- Scientific Data

- Patents

- In/Out-licensing

- Collaborations

- Analysts Comments

How May Drug Pipeline Update Be of Use?

- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

- Find competitors, collaborations partners, M&A candidates etc.

- Jump start competitive drug intelligence operations

- Excellent starting point for world wide benchmarking

- Compare portfolio and therapy focus with your peers

- Speed up pro-active in-/outlicensing strategy work

- Fast and easy way of tracking drugs using search engines; just one click and you may search World Wide Web and PubMed for any drug with all its synonyms.

Drug Pipeline Update is Delivered to You as a CD-ROM application

Drug Pipeline Update is fitted into a CD-ROM based application, for your intelligent usage:

- Smart CD-ROM application, which makes it easy to use and navigate by

- Multiple search and sort functions included

- Drug data is linked to search engines like Google and PubMed

- Direct links to web pages from inside the application

- Found information is easily shared with others over email, file export or in print

System Requirements

- AMD-Athlon/Pentium II PC

- Windows 98/NT4/2000/ME/XP

- 8x-speed CD Rom drive

- SVGA 16 bit display. (32 bit recommended)

- 32 MB of available RAM (128 MB recommended)

- Internet access (to test web-enabled presentations)

For more information visit http://www.researchandmarkets.com/reports/c45602

Source: Business Wire

More News in this Category